DBV Technologies - ADR
DBVT
Get informed when a big investor buys or sells
+ FollowMarket Cap$780.37M
Close$
$2.00
78.1% downside
Current Fair Value
78.1% downsideOvervalued by 78.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $780.37 Million |
|---|---|
| Enterprise Value | $613.17 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.7 |
| Beta | -0.21 |
| Outstanding Shares | 85,660,570 |
Return
| Return on Equity | -102.70% |
|---|---|
| Return on Assets | -73.81% |
| Return on Invested Capital | -50.62% |
Valuation & Multiples
| P/E Ratio | -2.41 |
|---|---|
| PEG | -9.09 |
| Price to Sales | - |
| Price to Book Ratio | 9.11 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.17 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-0.12
Average shareholder expectationRevenue Estimate
$913,083
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$-0.16
Average shareholder expectationRevenue Estimate
$760,680
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 25.13%▲ 0.41% |
|---|---|
| Total Invested | $345.69M▼ 20.27% |
| Investors Holding | 78▲ 6.00% |
ESG Score
No data
About DBV Technologies
170 employees
CEO: Daniel Tasse DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase II...